1. Type 2 diabetes (according to WHO diagnostic criteria),

2. Age range: 50 to ≦75 years,

3. Glycosylated hemoglobin (HbA1c): 6.5 to ≦9.0%,

4. Bone mineral density (lumbar spine, hip, or femoral neck) T-score < -1, or history of fragility fractures (hip, vertebral, distal forearm, or proximal humerus fractures) within three years before screening,

5. No use of antidiabetic medications in 8 weeks prior to enrollment (excluding metformin).

1. Bone mineral density (lumbar spine, hip, or femoral neck) T-score < -2.5,

2. History of secondary osteoporosis,

3. Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) > 2.5 times the upper limit of the normal reference, or estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73㎡),

4. History of malignant tumors,

5. Received strong anti-osteoporosis medications such as bisphosphonates, denosumab, or teriparatide within the past 2 years,

6. History of pancreatitis or triglyceride levels >5.6 mmol/L;

7. Family history of medullary carcinoma.